Evidence map›Paper›PMID 33691480›Full record

Trial reportArteriosclerosis, thrombosis, and vascular biology2021

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.

Laurens F Reeskamp, John S Millar, Liya Wu, Hans Jansen, Dewi van Harskamp, Henk Schierbeek, Daniel A Gipe, Daniel J Rader, Geesje M Dallinga-Thie, G Kees Hovingh and 1 more

Open access · hybridAbstract readMulticenter StudyClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 101 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Antibody-Based Therapeutics for Hypercholesterolemia.Biologics : targets & therapy · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Laurens F ReeskampDepartment of Vascular Medicine (L.F.R., G.K.H.), Amsterdam UMC, location AMC, University of Amsterdam, The Netherlands.
John S MillarInstitute for Diabetes, Obesity, and Metabolism (J.S.M.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Liya WuDivision of Translational Medicine and Human Genetics, Department of Medicine (J.S.M., L.W., D.J.R., M.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Hans JansenDepartment of Experimental Vascular Medicine (H.J.), Amsterdam UMC, location AMC, University of Amsterdam, The Netherlands.
Dewi van HarskampStable Isotope Research Laboratory, Endocrinology, Vrije Universiteit (D.v.H., H.S.), Amsterdam UMC, location AMC, University of Amsterdam, The Netherlands.
Henk SchierbeekStable Isotope Research Laboratory, Endocrinology, Vrije Universiteit (D.v.H., H.S.), Amsterdam UMC, location AMC, University of Amsterdam, The Netherlands.
Daniel A GipeRegeneron Pharmaceuticals, Inc, Tarrytown, NY (D.A.G.).
Daniel J RaderDivision of Translational Medicine and Human Genetics, Department of Medicine (J.S.M., L.W., D.J.R., M.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Geesje M Dallinga-Thie
G Kees HovinghDepartment of Vascular Medicine (L.F.R., G.K.H.), Amsterdam UMC, location AMC, University of Amsterdam, The Netherlands.
Marina CuchelDivision of Translational Medicine and Human Genetics, Department of Medicine (J.S.M., L.W., D.J.R., M.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Translational Therapeutics (United States) · USUniversity of Amsterdam · NLVrije Universiteit Amsterdam · NLAmsterdam University Medical Centers · NLRegeneron (United States) · US

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Physiological and therapeutic effects of ANGPTL3 variants in mice and humansR01HL148769 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CUCHEL, MARINA · 2019 to 2022
$3.0M
NCATS NIH HHS UL1 TR001878NHLBI NIH HHS R01 HL148769
6 · The paper itself

Abstract

[Figure: see text].

Indexed as

AdultAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAntibodies, MonoclonalAnticholesteremic AgentsApolipoprotein B-100BiomarkersCholesterol, LDLFemaleGenetic Predisposition to DiseaseHomozygoteHumansHyperlipoproteinemia Type IILipoproteins, IDLLipoproteins, LDLLiverAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAntibodies, MonoclonalAnticholesteremic AgentsAPOB protein, humanApolipoprotein B-100BiomarkersCholesterol, LDLevinacumabLDLR protein, humanLipoproteins, IDLLipoproteins, LDLReceptors, LDLangiopoietin-like proteincholesterol, LDLfamilial hypercholesterolemiaisotopeleucinelipoprotein

Identifiers

PMID33691480
PMCPMC8057526
OpenAlexW3135251972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.